Aug 29 (Reuters) - AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus, anifrolumab, met its main goal in a late-stage study.
The drug showed a “statistically-significant” and “clinically-meaningful” reduction in the disease in patients with systemic lupus erythematosus, commonly known as SLE, the company said. (Reporting by Noor Zainab Hussain in Bengaluru; Editing by Sriraj Kalluvila)
